A Sativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background and Purpose: S ativex® is an oromucosal spray, containing equivalent amounts of Δ 9‐tetrahydrocannabinol (Δ 9‐THC) and cannabidiol (CBD)‐botanical drug substance (BDS), which has been approved for the treatment of spasticity and pain associated to multiple sclerosis (MS). In this study, we investigated whether S ativex may also serve as a disease‐modifying agent in the T heiler's murine encephalomyelitis virus‐induced demyelinating disease model of MS. Experimental Approach: A S ativex‐like combination of phytocannabinoids and each phytocannabinoid alone were administered to mice once they had established MS‐like symptoms. Motor activity and the putative targets of these cannabinoids were assessed to evaluate therapeutic efficacy. The accumulation of chondroitin sulfate proteoglycans (CSPGs) and astrogliosis were assessed in the spinal cord and the effect of S ativex on CSPGs production was evaluated in astrocyte cultures. Key Results: Sativex improved motor activity – reduced CNS infiltrates, microglial activity, axonal damage – and restored myelin morphology. Similarly, we found weaker vascular cell adhesion molecule‐1 staining and IL‐1β gene expression but an up‐regulation of arginase‐1. The astrogliosis and accumulation of CSPGs in the spinal cord in vehicle‐infected animals were decreased by S ativex, as was the synthesis and release of CSPGs by astrocytes in culture. We found that CBD‐BDS alone alleviated motor deterioration to a similar extent as S ativex, acting through PPAR γ receptors whereas Δ 9‐THC‐BDS produced weaker effects, acting through CB2 and primarily CB1 receptors. Conclusions and Implications: The data support the therapeutic potential of S ativex to slow MS progression and its relevance in CNS repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 2×
“The activation of CB1 receptors probably mediates the neuroprotective effects of Δ9-THC as this receptor fulfils an important role in the defence against excitotoxicity (Marsicano et al., 2003) and excitotoxic mechanisms are prominent in TMEVIDD (Docagne et al., 2007).”
BackgroundPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 2×
“In MS, repair and remyelination occur in shadow plaques (Chang et al., 2012) but, as the disease progresses, remyelination becomes less efficient (Chang et al., 2002; Franklin, 2002; Goldschmidt et al., 2009).”
BackgroundMalfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Remyelination capacity of the MS brain decreases with disease chronicity
Goldschmidt, T., Antel, J., König, F. B., Brück, W., & Kuhlmann, T. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8260a · Cited by 411 · cited 2×
“In MS, repair and remyelination occur in shadow plaques (Chang et al., 2012) but, as the disease progresses, remyelination becomes less efficient (Chang et al., 2002; Franklin, 2002; Goldschmidt et al., 2009).”
BackgroundEsposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410 · cited 16×
“Inflammatory infiltrates were evaluated by scoring the infiltrate in the spinal cord on Table 1 Primary antibodies used for immunochemistry and Western blot analysis Antibody Host Dilution Source lba-1 Rabbit 1:1000 Wako, Osaka, Japan CD4 Rat IgG 1:1000 Pharmingen, San Diego, CA, USA CD8 Rat IgG 1:1000 Pharmingen, San…”
BackgroundInfluentialCortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216 · cited 3×
“It is unlikely that the inability to remyelinate results from the absence of oligodendrocyte precursor cells (OPCs) in the adult CNS, as OPCs are present in elderly patients even decades after having been diagnosed with the disease (Chang et al., 2012).”
BackgroundMecha, M., Torrao, A. S., Mestre, L., Carrillo-Salinas, F. J., Mechoulam, R., & Guaza, C. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.71 · Cited by 140
Self-citation
Cited by
Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Endocannabinoids drive the acquisition of an alternative phenotype in microglia
Mecha, M., Feliú, A., Carrillo-Salinas, F. J., Rueda-Zubiaurre, A., Ortega-Gutiérrez, S., de Sola, R. G., & Guaza, C. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.002 · Cited by 234
Self-citationTherapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“For example, in two different murine models of MS, Sativex slowed down MS progression by improving motor activity, reducing CNS infiltrates and microglial activity, together with promoting myelin repair (Feliú et al., 2015) and improving the neurological deficits and cell infiltrates within the CNS.”
Natural Products as a Potential Modulator of Microglial Polarization in Neurodegenerative Diseases
Jin, X., Liu, M.-Y., Zhang, D.-F., Zhong, X., Du, K., Qian, P., Gao, H., & Wei, M.-J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104253 · Cited by 109
Calina, D., Buga, A. M., Mitroi, M., Buha, A., Caruntu, C., Scheau, C., Bouyahya, A., El Omari, N., El Menyiy, N., & Docea, A. O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082395 · Cited by 65
The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia
Mecha, M., Yanguas-Casás, N., Feliú, A., Mestre, L., Carrillo-Salinas, F., Azcoitia, I., Yong, V. W., & Guaza, C. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.013 · Cited by 47
“…endocannabinoids (eCBs) exerts beneficial effects, limiting inflammation in the acute (Mestre et al., 2011; Mecha et al., 2013b, 2018) and chronic phase of the disease (Arévalo-Martín et al., 2003; Croxford and Miller 2003; Ortega-Gutiérrez et al., 2005; Feliú et al., 2015; Granja et al., 2012).”
Self-citation
Metadata
- Authors
- Feliú, A., Moreno‐Martet, M., Mecha, M., Carrillo‐Salinas, F. J., de Lago, E., Fernández‐Ruiz, J., & Guaza, C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2015-05-20
- Volume
- 172
- Issue
- 14
- Pages
- 3579-3595
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1833126618
- Cited by
- 70
- References
- 10
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.